Generated by AI
Lipocine Inc. is a biopharmaceutical company focused on developing oral drug delivery products that improve the administration of therapies that are traditionally difficult to formulate. The company’s current portfolio includes TLANDO, an oral testosterone replacement therapy for men with low testosterone, and LPCN 1154 (BRLIZIO™), an oral neurosteroid under development for postpartum depression. Lipocine also advances additional product candidates across hormone-related, liver, and women’s health areas, using its proprietary delivery technology platform to support convenient oral dosing and differentiated therapeutic profiles. Based in Salt Lake City, Utah, Lipocine operates in the specialty pharmaceuticals and clinical-stage biotechnology markets, with its work centered on translating complex drug molecules into patient-friendly oral treatments.
Website675 Arapeen Drive
Salt Lake City, UT, 84108
United States
The latest articles about LPCN.
Summary of Oct 16's posts. Generated by AI.
Summary of Oct 8's posts. Generated by AI.
Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced financial results for the third quarter ended September 30, 2026 and provided a corporate update.
Summary of Oct 16's posts. Generated by AI.
Investors talking about LPCN also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.